1887

Chapter 108 : Antiviral Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Antiviral Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap108-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap108-2.gif

Abstract:

The use of antiviral agents for the treatment of viral diseases continues to expand. Most of the agents currently approved by the Food and Drug Administration (FDA) are active against one or more of the following viruses: human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), hepatitis B and C viruses (HBV and HCV, respectively), the human herpesviruses, and influenza A and B viruses. This chapter is organized according to these virus groups, with cross-referencing for agents with activity against more than one group of viruses. There are now five classes of antiviral agents for treatment of HIV-1: (i) nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs), (ii) nonnucleoside reverse transcriptase inhibitors (NNRTIs), (iii) protease inhibitors (PIs), (iv) entry/fusion inhibitors, and (v) integrase strand transfer inhibitors (INSTIs). The only antiviral agents that have shown any activity in achieving a sustained virologic response against chronic HCV infection are standard interferon (IFN)-α; 2a and 2b, pegylated IFN-α; (PEG-IFN) 2aµ and 2b, and combinations of these IFNs with ribavirin (RBV). There are two major classes of drugs available to treat HBV: nucleoside and nucleotide analogues and IFNs. Most of the antiviral compounds that are approved to treat the eight human herpesviruses are nucleoside or nucleotide analogues which inhibit DNA replication. The two classes of antiviral agents for the treatment of influenza are M2 protein inhibitors (active only against type A influenza viruses) and neuraminidase inhibitors (activity against both type A and B viruses).

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108

Key Concept Ranking

Reverse Transcriptase Inhibitors
0.721399
Viral Diseases
0.55521655
Antiviral Drugs
0.5457119
Human immunodeficiency virus 1
0.5406014
0.721399
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555816728.chap108
1. Akuta, N.,, and H. Kumada. 2005. Influence of hepatitis B virus genotypes on the response to antiviral therapies. J. Antimicrob. Chemother. 55: 139 142.
2.American Academy of Pediatrics Committee on Infectious Diseases. 2007. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 119: 852860.
3. Avery, R. K.,, B. J. Bolwell,, B. Yen-Lieberman,, N. Lurain,, W. J. Waldman,, D. L. Longworth,, A. J. Taege,, S. B. Mossad,, D. Kohn,, J. R. Long,, J. Curtis,, M. Kalaycio,, B. Pohlman,, and J. W. Williams. 2004. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 34: 1071 1075.
4. Aweeka, F.,, J. Gambertoglio,, J. Mills,, and M. A. Jacobson. 1989. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob. Agents Chemother. 33: 742 745.
5. Bacon, T. H.,, M. J. Levin,, J. J. Leary,, R. T. Sarisky,, and D. Sutton. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16: 114 128.
6. Bean, B. 1992. Antiviral therapy: current concepts and practices. Clin. Microbiol. Rev. 5: 146 182.
7. Birnkrant, D.,, and E. Cox. 2009. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361: 2204 2207.
8. Boffito, M.,, D. Maitland,, Y. Samarasinghe,, and A. Pozniak. 2005. The pharmacokinetics of HIV protease inhibitor combinations. Curr. Opin. Infect. Dis. 18: 1 7.
9. Bonney, D.,, H. Razali,, A. Turner,, and A. Will. 2009. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br. J. Haematol. 145: 667 669.
10. Bowles, S. K.,, W. Lee,, A. E. Simor,, M. Vearncombe,, M. Loeb,, S. Tamblyn,, M. Fearon,, Y. Li,, and A. McGeer. 2002. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J. Am. Geriatr. Soc. 50: 608 616.
11. Brinkman, K.,, J. A. Smeitink,, J. A. Romijn,, and P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-analogue reversetranscriptase inhibitors is a key factor in the pathogenesis of antiretroviral- therapy-related lipodystrophy. Lancet 354: 1112 1115.
12. Briz, V.,, C. Garrido,, E. Poveda,, J. Morello,, P. Barreiro,, C. de Mendoza,, and V. Soriano. 2009. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res. Hum. Retrovir. 25: 225 227.
13. Calfee, D. P.,, and F. G. Hayden. 1998. New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs 56: 537 553.
14. Capparelli, E. V.,, S. L. Letendre,, R. J. Ellis,, P. Patel,, D. Holland,, and J. A. McCutchan. 2005. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 49: 2504 2506.
15. Carmine, A. A.,, R. N. Brogden,, R. C. Heel,, T. M. Speight,, and G. S. Avery. 1982. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 23: 329 353.
16. Casper, C.,, E. M. Krantz,, L. Corey,, S. R. Kuntz,, J. Wang,, S. Selke,, S. Hamilton,, M. L. Huang,, and A. Wald. 2008. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J. Infect. Dis. 198: 23 30.
17. Cass, L. M.,, C. Efthymiopoulos,, and A. Bye. 1999. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 36( Suppl.1): 1 11.
18. Castello, G.,, G. Mela,, A. Cerruti,, M. Mencoboni,, and R. Lerza. 1995. Azidothymidine and interferon-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Exp. Hematol. 23: 1367 1371.
19. Cheng, P. K.,, A. P. To,, T. W. Leung,, P. C. Leung,, C. W. Lee,, and W. W. Lim. 2010. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg. Infect. Dis. 16: 155 156.
20. Chilukuri, S.,, and T. Rosen. 2003. Management of acyclovirresistant herpes simplex virus. Dermatol. Clin. 21: 311 320.
21. Chrisp, P.,, and S. P. Clissold. 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41: 104 129.
22. Cimoch, P. J.,, J. Lavelle,, R. Pollard,, K. G. Griffy,, R. Wong,, T. L. Tarnowski,, S. Casserella,, and D. Jung. 1998. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17: 227 234.
23. Cooper, C. L.,, R. P. van Heeswijk,, K. Gallicano,, and D. W. Cameron. 2003. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36: 1585 1592.
24. Cooper, D. A.,, R. T. Steigbigel,, J. M. Gatell,, J. K. Rockstroh,, C. Katlama,, P. Yeni,, A. Lazzarin,, B. Clotet,, P. N. Kumar,, J. E. Eron,, M. Schechter,, M. Markowitz,, M. R. Loutfy,, J. L. Lennox,, J. Zhao,, J. Chen,, D. M. Ryan,, R. R. Rhodes,, J. A. Killar,, L. R. Gilde,, K. M. Strohmaier,, A. R. Meibohm,, M. D. Miller,, D. J. Hazuda,, M. L. Nessly,, M. J. DiNubile,, R. D. Isaacs,, H. Teppler,, and B. Y. Nguyen. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359: 355 365.
25. Cote, H. C.,, Z. L. Brumme,, K. J. Craib,, C. S. Alexander,, B. Wynhoven,, L. Ting,, H. Wong,, M. Harris,, P. R. Harrigan,, M. V. O’Shaughnessy,, and J. S. Montaner. 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346: 811 820.
26. Covens, K.,, K. Kabeya,, Y. Schrooten,, N. Dekeersmaeker,, E. Van Wijngaerden,, A. M. Vandamme,, S. De Wit,, and K. Van Laethem. 2009. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. J. Clin. Virol. 44: 325 328.
27. Crotty, S.,, D. Maag,, J. J. Arnold,, W. Zhong,, J. Y. Lau,, Z. Hong,, R. Andino,, and C. E. Cameron. 2000. The broadspectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6: 1375 1379.
28. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335: 721 729.
29. Cundy, K. C.,, B. G. Petty,, J. Flaherty,, P. E. Fisher,, M. A. Polis,, M. Wachsman,, P. S. Lietman,, J. P. Lalezari,, M. J. Hitchcock,, and H. S. Jaffe. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39: 1247 1252.
30. Curran, M.,, and S. Noble. 2001. Valganciclovir. Drugs 61: 1145 1150.
31. Cvetkovic, R. S.,, and K. Wellington. 2005. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65: 859 878.
32. De Clercq, E. 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33: 307 320.
33. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30: 115 133.
34. Dreitlein, W. B.,, J. Maratos,, and J. Brocavich. 2001. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin. Ther. 23: 327 355.
35. Durand-Gasselin, L.,, A. Pruvost,, A. Dehee,, G. Vaudre,, M. D. Tabone,, J. Grassi,, G. Leverger,, A. Garbarg-Chenon,, H. Benech,, and C. Dollfus. 2008. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob. Agents Chemother. 52: 2555 2563.
36. Earnshaw, D. L.,, T. H. Bacon,, S. J. Darlison,, K. Edmonds,, R. M. Perkins,, and R. A. Vere Hodge. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36: 2747 2757.
37. Efferth, T.,, M. R. Romero,, D. G. Wolf,, T. Stamminger,, J. J. Marin,, and M. Marschall. 2008. The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47: 804 811.
38. Eron, J. J., Jr. 2000. HIV-1 protease inhibitors. Clin. Infect. Dis. 30( Suppl. 2): S160 S170.
39. Este, J. A.,, and A. Telenti. 2007. HIV entry inhibitors. Lancet 370: 81 88.
40. Fellay, J.,, C. Marzolini,, L. Decosterd,, K. P. Golay,, P. Baumann,, T. Buclin,, A. Telenti,, and C. B. Eap. 2005. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 60: 865 873.
41. Fiore, A. E.,, D. K. Shay,, K. Broder,, J. K. Iskander,, T. M. Uyeki,, G. Mootrey,, J. S. Bresee,, and N. S. Cox. 2008. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep. 57: 1 60.
42. Fischl, M. A.,, D. D. Richman,, M. H. Grieco,, M. S. Gottlieb,, P. A. Volberding,, O. L. Laskin,, J. M. Leedom,, J. E. Groopman,, D. Mildvan,, R. T. Schooley, et al. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317: 185 191.
43. Fontana, R. J. 2009. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49: S185 S195.
44. Ford, J.,, S. H. Khoo,, and D. J. Back. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54: 982 990.
45. Foudraine, N. A.,, R. M. Hoetelmans,, J. M. Lange,, F. de Wolf,, B. H. van Benthem,, J. J. Maas,, I. P. Keet,, and P. Portegies. 1998. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351: 1547 1551.
46. Fried, M. W.,, M. L. Shiffman,, K. R. Reddy,, C. Smith,, G. Marinos,, F. L. Goncales, Jr.,, D. Haussinger,, M. Diago,, G. Carosi,, D. Dhumeaux,, A. Craxi,, A. Lin,, J. Hoffman,, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975 982.
47. Gallagher, T. Q.,, and C. S. Derkay. 2008. Recurrent respiratory papillomatosis: update 2008. Curr. Opin. Otolaryngol. Head Neck Surg. 16: 536 542.
48. Gallant, J. E.,, E. DeJesus,, J. R. Arribas,, A. L. Pozniak,, B. Gazzard,, R. E. Campo,, B. Lu,, D. McColl,, S. Chuck,, J. Enejosa,, J. J. Toole,, and A. K. Cheng. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354: 251 260.
49. Geary, R. S.,, S. P. Henry,, and L. R. Grillone. 2002. Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41: 255 260.
50. Ghany, M. G.,, D. B. Strader,, D. L. Thomas,, and L. B. Seeff. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335 1374.
51. Gish, R. G.,, H. Trinh,, N. Leung,, F. K. Chan,, M. W. Fried,, T. L. Wright,, C. Wang,, J. Anderson,, E. Mondou,, A. Snow,, J. Sorbel,, F. Rousseau,, and L. Corey. 2005. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. 43: 60 66.
52. Gulick, R. M.,, H. J. Ribaudo,, C. M. Shikuma,, S. Lustgarten,, K. E. Squires,, W. A. Meyer III,, E. P. Acosta,, B. R. Schackman,, C. D. Pilcher,, R. L. Murphy,, W. E. Maher,, M. D. Witt,, R. C. Reichman,, S. Snyder,, K. L. Klingman,, and D. R. Kuritzkes. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350: 1850 1861.
53. Harper, S. A.,, K. Fukuda,, T. M. Uyeki,, N. J. Cox,, and C. B. Bridges. 2004. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 53: 1 40.
54. Havlir, D. V.,, and S. D. O’Marro. 2004. Atazanavir: new option for treatment of HIV infection. Clin. Infect. Dis. 38: 1599 1604.
55. Havlir, D. V.,, C. Tierney,, G. H. Friedland,, R. B. Pollard,, L. Smeaton,, J. P. Sommadossi,, L. Fox,, H. Kessler,, K. H. Fife,, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182: 321 325.
56. Hayden, F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48( Suppl. 1): S3 S13.
57. Hayden, F. G.,, R. Belshe,, C. Villanueva,, R. Lanno,, C. Hughes,, I. Small,, R. Dutkowski,, P. Ward,, and J. Carr. 2004. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis. 189: 440 449.
58. Hayden, F. G.,, A. Minocha,, D. A. Spyker,, and H. E. Hoffman. 1985. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob. Agents Chemother. 28: 216 221.
59. Hazar, V.,, S. Kansoy,, A. Kupesiz,, S. Aksoylar,, M. Kantar,, and A. Yesilipek. 2004. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplant. 33: 931 935.
60. Hicks, C.,, and R. M. Gulick. 2009. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48: 931 939.
61. Hill, G.,, T. Cihlar,, C. Oo,, E. S. Ho,, K. Prior,, H. Wiltshire,, J. Barrett,, B. Liu,, and P. Ward. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion—correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30: 13 19.
62. Hsue, P. Y.,, P. W. Hunt,, Y. Wu,, A. Schnell,, J. E. Ho,, H. Hatano,, Y. Xie,, J. N. Martin,, P. Ganz,, and S. G. Deeks. 2009. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23: 2021 2027.
63. Hurt, A. C.,, J. K. Holien,, M. W. Parker,, and I. G. Barr. 2009. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 69: 2523 2531.
64. Isaac, A.,, S. Taylor,, P. Cane,, E. Smit,, S. E. Gibbons,, D. J. White,, S. M. Drake,, S. Khoo,, and D. J. Back. 2004. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J. Antimicrob. Chemother. 54: 498 502.
65. Ison, M. G.,, J. W. Gnann, Jr.,, S. Nagy-Agren,, J. Treannor,, C. Paya,, R. Steigbigel,, M. Elliott,, H. L. Weiss,, and F. G. Hayden. 2003. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8: 183 190.
66. Jabs, D. A.,, and P. D. Griffiths. 2002. Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. 133: 552 556.
67. Jain, M. K.,, L. Comanor,, C. White,, P. Kipnis,, C. Elkin,, K. Leung,, A. Ocampo,, N. Attar,, P. Keiser,, and W. M. Lee. 2007. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J. Viral Hepat. 14: 176 182.
68. Janssen, H. L.,, M. van Zonneveld,, H. Senturk,, S. Zeuzem,, U. S. Akarca,, Y. Cakaloglu,, C. Simon,, T. M. So,, G. Gerken,, R. A. de Man,, H. G. Niesters,, P. Zondervan,, B. Hansen,, and S. W. Schalm. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123 129.
69. Jing, X.,, C. Ma,, Y. Ohigashi,, F. A. Oliveira,, T. S. Jardetzky,, L. H. Pinto,, and R. A. Lamb. 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. USA 105: 10967 10972.
70. Johnson, L. B.,, and L. D. Saravolatz. 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis. 48: 1123 1128.
71. Kaplan, J. E.,, C. Benson,, K. H. Holmes,, J. T. Brooks,, A. Pau,, and H. Masur. 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58: 1 207.
72. Katz, D. H.,, J. F. Marcelletti,, M. H. Khalil,, L. E. Pope,, and L. R. Katz. 1991. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc. Natl. Acad. Sci. USA 88: 10825 10829.
73. Kim, C. U.,, B. Y. Luh,, and J. C. Martin. 1990. Synthesis and antiviral activity of ( S)-9-[4-hydroxy-3-(phosphonomethoxy) butyl]guanine. J. Med. Chem. 33: 1797 1800.
74. Kiser, J. J. 2008. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr. Opin. HIV AIDS 3: 330 341.
75. Koh, Y.,, S. Matsumi,, D. Das,, M. Amano,, D. A. Davis,, J. Li,, S. Leschenko,, A. Baldridge,, T. Shioda,, R. Yarchoan,, A. K. Ghosh,, and H. Mitsuya. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282: 28709 28720.
76. Kuypers, D. R.,, A. K. Vandooren,, E. Lerut,, P. Evenepoel,, K. Claes,, R. Snoeck,, L. Naesens,, and Y. Vanrenterghem. 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am. J. Transplant. 5: 1997 2004.
77. Laguno, M.,, C. Cifuentes,, J. Murillas,, S. Veloso,, M. Larrousse,, A. Payeras,, L. Bonet,, F. Vidal,, A. Milinkovic,, A. Bassa,, C. Villalonga,, I. Perez,, C. Tural,, M. Martinez- Rebollar,, M. Calvo,, J. L. Blanco,, E. Martinez,, J. M. Sanchez- Tapias,, J. M. Gatell,, and J. Mallolas. 2009. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49: 22 31.
78. Lampertico, P.,, M. Vigano,, E. Manenti,, M. Iavarone,, E. Sablon,, and M. Colombo. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133: 1445 1451.
79. Lau, G. K.,, T. Piratvisuth,, K. X. Luo,, P. Marcellin,, S. Thongsawat,, G. Cooksley,, E. Gane,, M. W. Fried,, W. C. Chow,, S. W. Paik,, W. Y. Chang,, T. Berg,, R. Flisiak,, P. McCloud,, and N. Pluck. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352: 2682 2695.
80. Leeds, J. M.,, S. P. Henry,, S. Bistner,, S. Scherrill,, K. Williams,, and A. A. Levin. 1998. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab. Dispos. 26: 670 675.
81. Legrand-Abravanel, F.,, F. Nicot,, A. Boulestin,, K. Sandres- Saune,, J. P. Vinel,, L. Alric,, and J. Izopet. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J. Med. Virol. 77: 66 69.
82. Lennox, J. L.,, E. DeJesus,, A. Lazzarin,, R. B. Pollard,, J. V. Madruga,, D. S. Berger,, J. Zhao,, X. Xu,, A. Williams-Diaz,, A. J. Rodgers,, R. J. Barnard,, M. D. Miller,, M. J. DiNubile,, B. Y. Nguyen,, R. Leavitt,, and P. Sklar. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796 806.
83. Leung, T. W.,, A. L. Tai,, P. K. Cheng,, M. S. Kong,, and W. Lim. 2009. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J. Clin. Virol. 46: 298 299.
84. Levi, M. E.,, N. Mandava,, L. K. Chan,, A. Weinberg,, and J. L. Olson. 2006. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl. Infect. Dis. 8: 38 43.
85. Levrero, M.,, T. Pollicino,, J. Petersen,, L. Belloni,, G. Raimondo,, and M. Dandri. 2009. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51: 581 592.
86. Leyssen, P.,, J. Balzarini,, E. De Clercq,, and J. Neyts. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79: 1943 1947.
87. Lietman, P. S. 1992. Clinical pharmacology: foscarnet. Am. J. Med. 92: 8S 11S.
88. Liu, V.,, G. S. Dhillon,, and D. Weill. 2010. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl. Infect. Dis. 12: 38 44.
89. Liu-Young, G.,, and M. J. Kozal. 2008. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 22: 449 457.
90. Luber, A. D.,, and J. F. Flaherty, Jr. 1996. Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother. 30: 978 985.
91. Ma, J. D.,, A. N. Nafziger,, S. A. Villano,, A. Gaedigk,, and J. S. Bertino, Jr. 2006. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, Nacetyltransferase- 2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 50: 1130 1135.
92. Machida, H. 1986. Comparison of susceptibilities of varicellazoster virus and herpes simplex viruses to nucleoside analogs. Antimicrob. Agents Chemother. 29: 524 526.
93. Magee, W. C.,, K. Y. Hostetler,, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49: 3153 3162.
94. Mallal, S.,, E. Phillips,, G. Carosi,, J. M. Molina,, C. Workman,, J. Tomazic,, E. Jagel-Guedes,, S. Rugina,, O. Kozyrev,, J. F. Cid,, P. Hay,, D. Nolan,, S. Hughes,, A. Hughes,, S. Ryan,, N. Fitch,, D. Thorborn,, and A. Benbow. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358: 568 579.
95. Manns, M. P.,, J. G. McHutchison,, S. C. Gordon,, V. K. Rustgi,, M. Shiffman,, R. Reindollar,, Z. D. Goodman,, K. Koury,, M. Ling,, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958 965.
96. Marcellin, P.,, G. K. Lau,, F. Bonino,, P. Farci,, S. Hadziyannis,, R. Jin,, Z. M. Lu,, T. Piratvisuth,, G. Germanidis,, C. Yurdaydin,, M. Diago,, S. Gurel,, M. Y. Lai,, P. Button,, and N. Pluck. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351: 1206 1217.
97. McMahon, M. A.,, B. L. Jilek,, T. P. Brennan,, L. Shen,, Y. Zhou,, M. Wind-Rotolo,, S. Xing,, S. Bhat,, B. Hale,, R. Hegarty,, C. R. Chong,, J. O. Liu,, R. F. Siliciano,, and C. L. Thio. 2007. The HBV drug entecavir—effects on HIV-1 replication and resistance. N. Engl. J. Med. 356: 2614 2621.
98. Menendez-Arias, L.,, and J. Tozser. 2008. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol. Sci. 29: 42 49.
99. Mertz, G. J.,, L. Miedzinski,, D. Goade,, A. T. Pavia,, B. Hjelle,, C. O. Hansbarger,, H. Levy,, F. T. Koster,, K. Baum,, A. Lindemulder,, W. Wang,, L. Riser,, H. Fernandez,, and R. J. Whitley. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39: 1307 1313.
100. Mmiro, F. A.,, J. Aizire,, A. K. Mwatha,, S. H. Eshleman,, D. Donnell,, M. G. Fowler,, C. Nakabiito,, P. M. Musoke,, J. B. Jackson,, and L. A. Guay. 2009. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J. Acquir. Immune Defic. Syndr. 52: 32 39.
101. Mohanty, S. R.,, and S. J. Cotler. 2005. Management of hepatitis B in liver transplant patients. J. Clin. Gastroenterol. 39: 58 63.
102. Monto, A. S. 2003. The role of antivirals in the control of influenza. Vaccine 21: 1796 1800.
103. Monto, A. S.,, S. E. Ohmit,, K. Hornbuckle,, and C. L. Pearce. 1995. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob. Agents Chemother. 39: 2224 2228.
104. Mould, D. R.,, X. Zhang,, K. Nieforth,, M. Salgo,, N. Buss,, and I. H. Patel. 2005. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatmentexperienced human immunodeficiency virus type 1-infected patients. Clin. Pharmacol. Ther. 77: 515 528.
105. Mould, J. A.,, J. E. Drury,, S. M. Frings,, U. B. Kaupp,, A. Pekosz,, R. A. Lamb,, and L. H. Pinto. 2000. Permeation and activation of the M2 ion channel of influenza A virus. J. Biol. Chem. 275: 31038 31050.
106. Naesens, L.,, L. Lenaerts,, G. Andrei,, R. Snoeck,, D. Van Beers,, A. Holy,, J. Balzarini,, and E. De Clercq. 2005. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 49: 1010 1016.
107. Nash, K. 2009. Telbivudine in the treatment of chronic hepatitis B. Adv. Ther. 26: 155 169.
108. Nguyen, J. T.,, J. D. Hoopes,, D. F. Smee,, M. N. Prichard,, E. M. Driebe,, D. M. Engelthaler,, M. H. Le,, P. S. Keim,, R. P. Spence,, and G. T. Went. 2009. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 53: 4115 4126.
109. Ormrod, D.,, L. J. Scott,, and C. M. Perry. 2000. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs 59: 839 863.
110. Orr, R. M. 2001. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc./CIBA Vision. Curr. Opin. Mol. Ther. 3: 288 294.
111. Orrick, J. J.,, and C. R. Steinhart. 2004. Atazanavir. Ann. Pharmacother. 38: 1664 1674.
112. Oxford, J. S. 2007. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respi. Viruses 1: 27 34.
113. Panelon AntiretroviralGuidelines for Adults and Adolescents. 1 December 2009, posting date. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults andAdolescents, p. 1161. U.S.Department of Health and Human Services, Washington,DC. http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf.
114. Patterson, J. L.,, and R. Fernandez-Larsson. 1990. Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 12: 1139 1146.
115. Pepose, J. S.,, T. P. Margolis,, P. LaRussa,, and D. Pavan- Langston. 2003. Ocular complications of smallpox vaccination. Am. J. Ophthalmol. 136: 343 352.
116. Perinatal HIV Guidelines Working Group. Public Health Service Task Force. 29 April 2009, posting date. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV Transmission in the United States, p. 190. U.S. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.>
117. Perronne, C. 2006. Antiviral hepatitis and antiretroviral drug interactions. J. Hepatol. 44: S119 S125.
118. Perry, C. M. 2009. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Drugs 69: 843 857.
119. Pescovitz, M. D.,, J. Rabkin,, R. M. Merion,, C. V. Paya,, J. Pirsch,, R. B. Freeman,, J. O’Grady,, C. Robinson,, Z. To,, K. Wren,, L. Banken,, W. Buhles,, and F. Brown. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44: 2811 2815.
120. Piscitelli, S. C.,, and K. D. Gallicano. 2001. Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. 344: 984 996.
121. Poveda, E.,, P. Barreiro,, B. Rodes,, and V. Soriano. 2005. Enfuvirtide is active against HIV type 1 group O. AIDS Res. Hum. Retrovir. 21: 583 585.
122. Preston, S. L.,, G. L. Drusano,, P. Glue,, J. Nash,, S. K. Gupta,, and P. McNamara. 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob. Agents Chemother. 43: 2451 2456.
123. Pruvost, A.,, E. Negredo,, H. Benech,, F. Theodoro,, J. Puig,, E. Grau,, E. Garcia,, J. Molto,, J. Grassi,, and B. Clotet. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49: \ 1914.
124. Ray, A. S.,, L. Olson,, and A. Fridland. 2004. Role of purine nucleoside phosphorylase in interactions between 2 ',3 '- dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48: 1089 1095.
125. Reischig, T.,, P. Jindra,, J. Mares,, M. Cechura,, M. Svecova,, O. Hes,, K. Opatrny, Jr., and V. Treska. 2005. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79: 317 324.
125a. Sarrazin, C.,, and S. Zeuzem. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447 462.
126. Schmidt, A. C. 2004. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 64: 2031 2046.
127. Schmid-Wendtner, M. H.,, and H. C. Korting. 2004. Penciclovir cream—improved topical treatment for herpes simplex infections. Skin Pharmacol. Physiol. 17: 214 218.
128. Schwarz, A.,, and A. Perez-Canto. 1998. Nephrotoxicity of antiinfective drugs. Int. J. Clin. Pharmacol. Ther. 36: 164 167.
129. Sen, G. C. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55: 255 281.
130. Shapira, M. Y.,, I. B. Resnick,, S. Chou,, A. U. Neumann,, N. S. Lurain,, T. Stamminger,, O. Caplan,, N. Saleh,, T. Efferth,, M. Marschall,, and D. G. Wolf. 2008. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46: 1455 1457.
131. Shehab, N.,, B. V. Sweet,, and N. D. Hogikyan. 2005. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 25: 977 989.
132. Shire, N. J.,, and K. E. Sherman. 2005. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin. Infect. Dis. 41( Suppl. 1): S63 S68.
133. Simpson, D.,, and K. A. Lyseng-Williamson. 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 66: 2397 2416.
134. Smee, D. F.,, B. L. Hurst,, M. H. Wong,, K. W. Bailey,, and J. D. Morrey. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53: 2120 2128.
135. Soriano, V.,, M. G. Peters,, and S. Zeuzem. 2009. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48: 313 320.
136. Soriano, V.,, M. Puoti,, M. Bonacini,, G. Brook,, A. Cargnel,, J. Rockstroh,, C. Thio,, and Y. Benhamou. 2005. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 19: 221 240.
137. Soriano, V.,, M. Puoti,, M. Peters,, Y. Benhamou,, M. Sulkowski,, F. Zoulim,, S. Mauss,, and J. Rockstroh. 2008. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22: 1399 1410.
138.StrategiesforManagementofAnti-RetroviralTherapy/INSIGHTandDADStudyGroups. 2008. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22: F17F24.
139. Sun, H. Y.,, M. M. Wagener,, and N. Singh. 2008. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant. 8: 2111 2118.
140. Suzuki, Y.,, R. Saito,, H. Zaraket,, C. Dapat,, I. Caperig-Dapat,, and H. Suzuki. 2010. Rapid and specific detection of amantadine- resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. J. Clin. Microbiol. 48: 57 63.
141. Talarico, C. L.,, T. C. Burnette,, W. H. Miller,, S. L. Smith,, M. G. Davis,, S. C. Stanat,, T. I. Ng,, Z. He,, D. M. Coen,, B. Roizman,, and K. K. Biron. 1999. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother. 43: 1941 1946.
142. Teo, M.,, and P. Hayes. 2004. Management of hepatitis C. Br. Med. Bull. 70: 51 69.
143. Torres-Madriz, G.,, and H. W. Boucher. 2008. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis. 47: 702 711.
144. Tozzi, V.,, P. Balestra,, M. F. Salvatori,, C. Vlassi,, G. Liuzzi,, M. L. Giancola,, M. Giulianelli,, P. Narciso,, and A. Antinori. 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52: 56 63.
145. Trofe, J.,, L. Pote,, E. Wade,, E. Blumberg,, and R. D. Bloom. 2008. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann. Pharmacother. 42: 1447 1457.
146. Vandekerckhove, L.,, C. Verhofstede,, and D. Vogelaers. 2009. Maraviroc: perspectives for use in antiretroviral-naive HIV-1- infected patients. J. Antimicrob. Chemother. 63: 1087 1096.
147. Vere Hodge, R. A.,, D. Sutton,, M. R. Boyd,, M. R. Harnden,, and R. L. Jarvest. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut- l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33: 1765 1773.
148. Walmsley, S.,, A. Avihingsanon,, J. Slim,, D. J. Ward,, K. Ruxrungtham,, J. Brunetta,, U. F. Bredeek,, D. Jayaweera,, C. J. Guittari,, P. Larson,, M. Schutz,, and F. Raffi. 2009. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J. Acquir. Immune Defic. Syndr. 50: 367 374.
149. Whitley, R. J. 2007. The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opin. Drug Metab. Toxicol. 3: 755 767.
150. Whitley, R. J.,, S. J. Soong,, R. Dolin,, G. J. Galasso,, L. T. Ch’ien,, and C. A. Alford. 1977. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N. Engl. J. Med. 297: 289 294.
151. Wiltshire, H.,, C. V. Paya,, M. D. Pescovitz,, A. Humar,, E. Dominguez,, K. Washburn,, E. Blumberg,, B. Alexander,, R. Freeman,, N. Heaton,, and K. P. Zuideveld. 2005. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79: 1477 1483.
152. Wintermeyer, S. M.,, and M. C. Nahata. 1995. Rimantadine: a clinical perspective. Ann. Pharmacother. 29: 299 310.
153. Wire, M. B.,, M. J. Shelton,, and S. Studenberg. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45: 137 168.
154. Wolf, D. L.,, C. A. Rodriguez,, M. Mucci,, A. Ingrosso,, B. A. Duncan,, and D. J. Nickens. 2003. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J. Clin. Pharmacol. 43: 43 51.
155. Working Groupon AntiretroviralTherapyand Medical Management of HIV-Infected Children. 23 February 2009, posting date. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. U.S.Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf.
156. Xiong, X.,, J. L. Smith,, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41: 594 599.
157. Yeni, P. 2003. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune Defic. Syndr. 34( Suppl. 1): S91 S94.
158. Youle, M. 2007. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J. Antimicrob. Chemother. 60: 1195 1205.
159. Younger, H. M.,, A. J. Bathgate,, and P. C. Hayes. 2004. Nucleoside analogues for the treatment of chronic hepatitis B. Aliment. Pharmacol. Ther. 20: 1211 1230.
160. Zeldin, R. K.,, and R. A. Petruschke. 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53: 4 9.

Tables

Generic image for table
TABLE 1

Antiviral agents for HIV therapy

Pharmaceutical companies: Abbott Laboratories, North Chicago, IL; BI, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT; BMS, Bristol-Myers Squibb, Princeton, NJ; Gilead Sciences, Foster City, CA; GSK, GlaxoSmithKline, Research Triangle Park, NC; Merck & Co., Whitehouse Station, NJ; Pfizer, New York, NY; Roche Pharmaceuticals, Nutley, NJ; Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., Raritan, NJ.

Gastrointestinal (GI) symptoms include nausea, vomiting, and diarrhea.

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108
Generic image for table
TABLE 2

Antiviral agents for HCV therapy

Pharmaceutical companies: Roche Pharmaceuticals, Nutley, NJ; S-P, Schering-Plough, Kenilworth, NJ.

Gastrointestinal (GI) symptoms include nausea, vomiting, and diarrhea.

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108
Generic image for table
TABLE 3

Antiviral agents for HBV therapy

Pharmaceutical companies: BMS, Bristol-Myers Squibb, Princeton, NJ; Gilead Sciences, Foster City, CA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108
Generic image for table
TABLE 4

Antiviral agents for herpesviruses

Pharmaceutical companies: AstraZeneca, Wilmington, DE; BMS, Gilead Sciences, Foster City, CA; GSK, GlaxoSmithKline, Research Triangle Park, NC; Monarch Pharmaceutical, Bristol, TN; Novartis, East Hanover, NJ; Roche Pharmaceuticals, Nutley, NJ.

Gastrointestinal (GI) symptoms include nausea, vomiting, and diarrhea.

Valacyclovir is used in some transplant settings for HCMV prophylaxis.

Cidofovir also has reported activity against human papillomavirus, polyomavirus, adenovirus, and poxvirus.

Ganciclovir and valganciclovir also have in vitro activity against EBV, HHV-6, HHV-7, and HHV-8.

Penciclovir is used to treat herpes labialis but also has activity against HSV-2 and VZV.

Vidarabine has in vitro activity against vaccinia virus and VZV.

Trifluridine is used to treat herpes keratitis but also has activity against HSV-2 and VZV.

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108
Generic image for table
TABLE 5

Antiviral agents for influenza viruses

Pharmaceutical companies: Endo Pharmaceuticals Inc., Chadds Ford, PA; Forrest Laboratories, Inc., St. Louis, MO; Roche Laboratories Inc., Nutley, NJ (licensor, Gilead Sciences, Inc., Foster City, CA); GSK, GlaxoSmithKline, Research Triangle Park, NC.

CNS symptoms include confusion, anxiety, insomnia, difficulty concentrating, dizziness, hallucinations, and seizures; gastrointestinal (GI) symptoms include nausea, vomiting, and anorexia; neuropsychiatric symptoms include self-injury and delirium.

Citation: Lurain N, Thompson K. 2011. Antiviral Agents, p 1687-1709. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch108

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error